195 related articles for article (PubMed ID: 38612439)
1. Analysis of the Gene Networks and Pathways Correlated with Tissue Differentiation in Prostate Cancer.
Filippi A; Aurelian J; Mocanu MM
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612439
[TBL] [Abstract][Full Text] [Related]
2. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
5. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
6. Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency.
Yeh HY; Cheng SW; Lin YC; Yeh CY; Lin SF; Soo VW
BMC Med Genomics; 2009 Dec; 2():70. PubMed ID: 20025723
[TBL] [Abstract][Full Text] [Related]
7. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
8. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
9. Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients.
Cai J; Chen Z; Chen X; Huang H; Lin X; Miao B
Biomed Res Int; 2020; 2020():4264291. PubMed ID: 32953881
[TBL] [Abstract][Full Text] [Related]
10. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
12. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract][Full Text] [Related]
13.
Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
[TBL] [Abstract][Full Text] [Related]
14. Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer.
Lehrer S; Rheinstein PH
Cancer Genomics Proteomics; 2020; 17(3):271-275. PubMed ID: 32345668
[TBL] [Abstract][Full Text] [Related]
15. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of biomarkers for prostate cancer based on weighted gene co-expression network analysis.
Chen X; Wang J; Peng X; Liu K; Zhang C; Zeng X; Lai Y
Medicine (Baltimore); 2020 Apr; 99(14):e19628. PubMed ID: 32243390
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
18. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
Piao XM; Byun YJ; Jeong P; Ha YS; Yoo ES; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
[TBL] [Abstract][Full Text] [Related]
19. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract][Full Text] [Related]
20. Coexpression Analysis of the EZH2 Gene Using The Cancer Genome Atlas and Oncomine Databases Identifies Coexpressed Genes Involved in Biological Networks in Breast Cancer, Glioblastoma, and Prostate Cancer.
Zhu J; Jin L; Zhang A; Gao P; Dai G; Xu M; Xu L; Yang D
Med Sci Monit; 2020 Jun; 26():e922346. PubMed ID: 32595202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]